Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 22 10:21AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.46 Insider Own20.80% Shs Outstand78.37M Perf Week9.00%
Market Cap447.04M Forward P/E- EPS next Y-1.15 Insider Trans1.69% Shs Float72.19M Perf Month10.47%
Income-120.74M PEG- EPS next Q-0.25 Inst Own86.05% Short Float8.36% Perf Quarter-1.90%
Sales0.00M P/S- EPS this Y40.29% Inst Trans10.22% Short Ratio3.15 Perf Half Y90.12%
Book/sh2.90 P/B1.69 EPS next Y-9.10% ROA-42.15% Short Interest6.04M Perf Year-17.70%
Cash/sh2.91 P/C1.69 EPS next 5Y38.60% ROE-50.60% 52W Range1.57 - 8.40 Perf YTD8.04%
Dividend Est.- P/FCF- EPS past 5Y-29.69% ROI-41.50% 52W High-41.61% Beta1.29
Dividend TTM- Quick Ratio20.62 Sales past 5Y0.00% Gross Margin- 52W Low212.42% ATR (14)0.39
Dividend Ex-Date- Current Ratio20.62 EPS Y/Y TTM40.91% Oper. Margin0.00% RSI (14)50.47 Volatility8.10% 8.07%
Employees71 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price14.50
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q60.82% Payout- Rel Volume0.48 Prev Close4.80
Sales Surprise- EPS Surprise38.18% Sales Q/Q- EarningsMay 13 BMO Avg Volume1.92M Price4.91
SMA204.47% SMA50-9.90% SMA20027.60% Trades Volume161,320 Change2.19%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Upgrade JP Morgan Neutral → Overweight $11
Dec-21-23Upgrade BofA Securities Neutral → Buy $4 → $6
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
May-20-24 09:35AM
May-16-24 04:05PM
May-13-24 02:53PM
May-09-24 08:00AM
12:30PM Loading…
May-07-24 12:30PM
May-01-24 10:15AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
12:00PM Loading…
Apr-01-24 12:00PM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
06:30AM Loading…
Dec-27-23 06:30AM
Dec-20-23 05:27PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
May-05-22 06:30AM
Apr-21-22 06:02AM
Apr-18-22 10:35AM
Apr-07-22 06:30AM
Apr-04-22 06:30AM
Mar-03-22 04:01PM
Mar-01-22 04:01PM
Feb-28-22 06:30AM
Jan-20-22 06:30AM
Jan-05-22 05:10PM
Jan-04-22 04:05PM
Dec-31-21 08:30AM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson William H.DirectorMay 01 '24Buy4.683,20014,9826,400May 03 04:15 PM
Carson William H.DirectorApr 08 '24Buy6.073,20019,4113,200Apr 10 07:17 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 20 '24Sale5.512,60414,34872,471Feb 21 04:31 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 20 '24Sale5.532,59314,33982,058Feb 21 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 20 '24Sale5.481,95110,69185,641Feb 21 04:31 PM
Love DouglasPRESIDENT AND CEOFeb 12 '24Sale5.545,78232,032196,121Feb 14 07:56 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 12 '24Sale5.541,81010,02736,075Feb 14 07:52 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 12 '24Sale5.541,80910,02245,651Feb 14 07:54 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 12 '24Sale5.531,3497,46048,592Feb 14 07:59 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Option Exercise1.6321,00034,17621,000Dec 29 04:12 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Sale4.5221,00094,9660Dec 29 04:12 PM
Satter Muneer ADirectorDec 26 '23Buy2.88350,0001,008,0007,406,024Dec 28 04:30 PM
Lew JenniferEVP & Chief Financial OfficerJul 11 '23Sale3.841,0574,05547,460Jan 23 04:57 PM
Overdorf MichaelEVP & Chief Business OfficerJul 11 '23Sale3.849783,75245,802Jan 23 04:58 PM
Bain Capital Life Sciences Inv10% OwnerMay 25 '23Buy2.13300,000639,7205,701,926May 30 09:54 PM